Previous 10 | Next 10 |
On April 12th, Altimmune ( ALT ) presented Phase I HepTcell data at the International Liver Congress in Vienna, Austria. Altimmune's immunotherapeutic synthetic peptide vaccine candidate demonstrated admirable safety and justified the company's plan to move into a Phase II study. Admittedly,...
Arbutus Biopharma Corp. (ABUS) Q4 2018 Results Conference Call March 07, 2019 04:30 PM ET Company Participants Pam Murphy - Investor Relations Mark Murray - CEO Mike Sofia - Chief Scientific Officer Gaston Picchio - Chief Development Officer Dave Hastings - Chief Financial Of...
Arbutus Biopharma (NASDAQ: ABUS ): FY GAAP EPS of -$1.21 misses by $0.03 . Revenue of $5.9M (-44.9% Y/Y) beats by $0.57M . Press Release More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news, ,
- Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a novel orally-available RNA destabilizer, with a go/no go decision expected in the second half of the year ...
WARMINSTER, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark Murray, Arbutus’ President and CEO, will present a corporate overview and busines...
WARMINSTER, Pa., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and year-end 2018 financial results conference call and webcas...
NEW YORK, Feb. 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Amarin Corporation PLC (NASDAQ:AMRN), Retrophin, Inc. (NASDAQ:RTRX), Sunr...
Arbutus Biopharma Corp (ABUS) Q3 2018 Earnings Conference Call November 7, 2018 04:30 pm ET Executives Pam Murphy - IR Mark Murray - President and CEO Mike Sofia - CSO David Hastings - CFO Analysts Liisa Bayko - JMP Securities Katherine Xu - William Blair Keay Nakae -...
Arbutus Biopharma (NASDAQ: ABUS ): Q3 GAAP EPS of -$0.49 misses by $0.08 . Revenue of $1.6M (-76.8% Y/Y) Press Release More news on: Arbutus Biopharma Corp, Earnings news and commentary, Healthcare stocks news,
- AB-506, a second-generation capsid inhibitor, advanced to HBV patient portion of Phase 1a/1b clinical trial - ONPATTRO™ (patisiran) approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), triggering a royalty stream to Arbutus ...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage bio...
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor tar...
WARMINSTER, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepa...